1. Reserpine attenuates biofilm formation and virulence of Staphylococcus aureus.
- Author
-
Parai D, Banerjee M, Dey P, and Mukherjee SK
- Subjects
- Anti-Bacterial Agents chemistry, Bacterial Proteins chemistry, Bacterial Proteins metabolism, Chemical Phenomena, Dose-Response Relationship, Drug, Drug Synergism, Hemolysis, Microbial Sensitivity Tests, Microbial Viability drug effects, Models, Molecular, Protein Binding, Reserpine chemistry, Staphylococcal Infections drug therapy, Structure-Activity Relationship, Anti-Bacterial Agents pharmacology, Biofilms drug effects, Reserpine pharmacology, Staphylococcal Infections microbiology, Staphylococcus aureus drug effects, Staphylococcus aureus physiology, Virulence drug effects
- Abstract
This study investigated the effects of reserpine, the main bioactive compound of Rauwolfia serpentina, on biofilm formation and biofilm-associated virulence factors production in a Gram-positive pathogen, Staphylococcus aureus. Crystal violet assay, MTT assay, Congo red binding, CLSM studies were performed to assess the antibiofilm activity. Molecular docking was performed to explain the possible mode of action, catheter model was used to evaluate its application potential and the combinatorial study was performed in search of an improved therapeutic formulation. Reserpine affected biofilm formation, EPS production, biofilm cell viability and virulence factor production. It could eradicate 72.7% biofilm at ½ × MIC dose and could also stop the metabolic activity of 50.6% bacterial cells in a biofilm. Staphylococcus aureus biofilm- and virulence-regulatory proteins like AgrA, AtlE, Bap, IcaA, SarA and SasG were found to interact with reserpine which might lead to the attenuation of its pathogenicity. Reserpine along with other commercial antibiotics could generate a hightened antibiofilm response, and also eradicated a good percentage of bacterial biofilm from a urinary catheter model. These findings suggested reserpine as a good alternative entity to generate new improved therapeutic formulations., Competing Interests: Declaration of competing interest The authors have no competing interests in any form., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF